Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →
CLEATUS
Get CLEATUS

Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not Allowed)

Open
RFA-AI-28-014Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is seeking proposals under solicitation RFA-AI-28-014 for the Systems Biology of Infection and Inflammation in Chronic Diseases. This initiative aims to advance the systems-level understanding of how infectious pathogens and inflammatory pathways contribute to the predisposition, onset, and progression of chronic diseases. The program emphasizes the integration of clinical and patient data, large-scale omics datasets, and advanced artificial intelligence and computational modeling to develop strategies for preventing, treating, and mitigating the combined effects of these conditions. This federal solicitation was posted on November 4, 2026, with a response deadline of February 19, 2027. It is important to note that clinical trials are not allowed under this specific funding opportunity. Interested parties can find further details through the provided grants portal.

General Info

NIAID seeks proposals for systems biology research on infection and chronic disease inflammation.

Agency

National Institutes Of Health → National Institute Of Allergy And Infectious Diseases

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Not specified

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseSolicitation
Posted

Solicitation

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyNational Institutes Of Health → National Institute Of Allergy And Infectious Diseases
ContactsNo contacts available
OfficeUSA
Organization / AgencyNational Institutes Of Health → National Institute Of Allergy And Infectious Diseases
Office AddressUSA
ContactsNo contact information available

Full Description

Show more
The purpose of this notice of funding opportunity (NOFO) is to support the advancement of systems-level understanding of the link between infectious pathogens and inflammatory pathways that result in predisposition, onset and progression of chronic diseases. The NOFO will stimulate integration of clinical and patient data, large-scale omics datasets, advanced Artificial Intelligence (AI) and computational modeling to prevent, treat, and mitigate the combined impact of chronic diseases, inflammation, and infections.

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Federal
Future Program: Laguna
Solicitation # DARPA-SN-27-15
Special Notice DARPA-SN-27-15, issued by the Defense Advanced Research Projects Agency Biological Technologies Office, serves as a public notification for the forthcoming Laguna program. This notice is intended for information and program planning purposes and does not constitute a formal solicitation for proposals. The program is anticipated to be a 36-month effort focused on the development and demonstration of defense-relevant specialty products formulated from U.S.-produced raw materials. These products must meet or exceed the critical performance requirements of existing military materials. Key deliverables for the program include predictive tools for material properties, life cycle assessments, technoeconomic analyses, and commercialization strategy plans. The primary point of contact for the initiative is Dr. William Mounfield. While this notice provides an overview of research interests, DARPA will not accept submissions at this time. Formal solicitation details and submission instructions will be posted on sam.gov upon release. All communications regarding this notice must remain unclassified.
Defense Advanced Research Projects Agcy

POSTED

about 19 hours ago

DEADLINE

in 24 days
View Details
NAICS: 541714
New
Grant
Cooperative Agreement for affiliated Partner with Rocky Mountain Cooperative Ecosystem Studies Unit
Solicitation # G27AS00062
The U.S. Geological Survey is seeking a CESU partner through a Cooperative Agreement to improve the efficiency and standardization of Real-Time Quaking Induced Conversion (RT-QuIC) assay data analysis for Chronic Wasting Disease (CWD) surveillance. The project aims to replace subjective interpretation with a robust, automated analytical pipeline. Key deliverables include the development of machine-learning models using LSTM, CNN-LSTM, or hybrid architectures to classify fluorescence curves, the creation of an open-source application using R-Shiny or Streamlit/Python for data ingestion and visualization, and the production of a peer-reviewed publication. To ensure reliability, the partner must perform cross-lab validations across at least three independent laboratories, including the USGS National Wildlife Health Center and the University of Georgia's Southeastern Cooperative Wildlife Disease Research Study. The opportunity has a total program funding and award ceiling of 145,220 dollars, with an anticipated period of performance from April 1, 2027, to March 31, 2032. Applications must be submitted via grants.gov by December 8, 2026, and must be submitted by an Authorized Organization Representative. Proposals are evaluated based on purpose and relevance, technical approach, qualifications and past performance, and budget clarity. Applicants must be registered in SAM.gov and provide a Unique Entity Identifier. The award is governed by DOI and USGS Terms and Conditions, and compliance with various 2 CFR 200 regulations regarding monitoring, reporting, and risk assessment is required.
US Geological Survey

POSTED

1 day ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Grant
Cooperative Agreement for affiliated Partner with Gulf Coast Cooperative Ecosystem Studies Unit
Solicitation # G27AS00064
The U.S. Geological Survey (USGS) Eastern Ecological Science Center is soliciting applications for a cooperative agreement under solicitation G27AS00064 to conduct bioinformatic analysis of avian microbiome metatranscriptomic datasets. This research focuses on the genome assembly-based identification of viruses, prokaryotic, and eukaryotic microorganisms, with a specific emphasis on wildlife and zoonotic pathogens. The project involves analyzing shotgun metatranscriptomic data to identify taxonomic domains and estimate microbial diversity and abundance across various host species, tissues, and geographic regions. Awardees are expected to develop reproducible bioinformatic workflows, collaborate on peer-reviewed publications, and make derived data products available through repositories like ScienceBase or the National Center for Biotechnology Information. The program has a total funding ceiling of 459,000 dollars with one expected award. The anticipated period of performance runs from April 1, 2027, to March 31, 2030. Applications must be submitted via grants.gov by December 7, 2026, and must be submitted by an Authorized Organization Representative. Proposals are evaluated based on purpose and relevance, technical approach, qualifications and past performance, and budget justification. Applicants must be registered in SAM.gov to obtain a Unique Entity Identifier and must provide a signed biographical sketch and current and pending support documentation. Payments will be administered through the Department of the Treasury Automated Standard Application for Payments system.
US Geological Survey

POSTED

1 day ago

DEADLINE

in about 2 months
View Details
NAICS: 541714
New
Federal
Immunohistochemical (IHC) Analysis SupportThe Immunohistochemical (IHC) Analysis Support subcontract, issued by the NASA Shared Services Center, involves providing specialized staining and chemical analysis of sectioned tissue for prime contractors on NASA Space Biosciences projects. The scope of work requires the application of antibodies and reagents to cryo-sectioned slides and the use of fluorescence microscopes and IHC staining stations to evaluate neuronal morphology. Due to the technical nature of the work, specialized training in neuro-histology is required to deliver the final analyzed slides and digital imaging reports. This opportunity is categorized under NAICS code 541714 and is associated with a performance location in zip code 94035. The solicitation was posted on November 4, 2026, with a response deadline of November 9, 2026.
NASA Shared Services Center

POSTED

2 days ago

DEADLINE

in 3 days
View Details
NAICS: 541714
New
Federal
Service request for specimen embedding and sectioning.
Solicitation # 80NSSC27948767Q
The NASA Shared Services Center is seeking custom histology research services to support a Space Biosciences Project evaluating neuronal morphology in mouse brains exposed to radiation, isolation, and simulated microgravity. The scope of work involves planning, preliminary testing, embedding, and cryo-sectioning of specific brain regions, including the substantia nigra, hippocampus, and prefrontal cortex. The contractor must provide slides with sections 15 microns thick, which are to be delivered to Principal Investigator Dr. Joshua Alwood within 90 days after receipt of order. Performance will be located at the NASA Ames Research Center. This procurement is being conducted under FAR Part 12 for commercial items and services, with the government intending to issue a sole source contract to ZYAGEN, identified as the sole provider of the required services. While the agency is currently requesting capability statements from interested organizations by November 9, 2026, to determine if a competitive procurement is feasible, it explicitly states that quotes will not be reviewed or accepted at this stage. Primary coordination for this effort is managed by Cara Craft and Will Garrett.
NASA Shared Services Center

POSTED

2 days ago

DEADLINE

in 3 days
View Details
NAICS: 541714
New
SBIR / STTR
Specialized Bio-Research / Protocol Compliance ConsultantThis subcontract opportunity is for a Specialized Bio-Research / Protocol Compliance Consultant to support research and development projects for the United States Navy and Marine Corps Systems Command. The selected provider will conduct research involving recombinant DNA and human or animal subjects, ensuring all activities are executed according to strict research protocols. Key responsibilities include managing recombinant DNA activities within laboratory facilities and maintaining full compliance with federal, state, and local environmental laws regarding the handling of toxic materials. All work must be performed under the necessary IRB and IACUC approvals, with the final deliverables consisting of experimental data and feasibility reports. The contract is designated as a Total Small Business Set-Aside under NAICS code 541714, specifically targeting firms with fewer than 500 employees in alignment with SBIR/STTR mandates. Interested parties must submit their responses by December 2, 2026. This role is critical for prime contractors requiring specialized expertise in bio-research compliance and the technical execution of complex laboratory protocols within the Department of Defense framework.
United States Navy

POSTED

2 days ago

DEADLINE

in 26 days
View Details
NAICS: 541714
New
SBIR / STTR
Biolab Mirror: Artificial Intelligence / Machine Learning (AI/ML) Digital Twin for Intent Characterization and Bio-Containment Integrity
Solicitation # DTR27TZ02-NV001
The Defense Threat Reduction Agency, under the Department of War, is soliciting proposals for the Biolab Mirror, an AI/ML-driven Digital Twin designed to ensure bio-containment integrity and characterize intent in state-sponsored biological research facilities. The project implements a Physics-to-Mesh Zero Trust architecture that cross-validates digital telemetry from LIMS, SCADA, and BMS logs against unalterable physical and biological laws, such as thermodynamics and metabolic rates. This system aims to detect clandestine pathogen scaling and containment spoofing by identifying coherence failures. Beyond its defensive application, the Biolab Mirror will serve as a cyber-physical sandbox for simulating multi-domain attacks against high-containment infrastructure, filling a critical gap in current cyber-range emulation. This is a phased STTR program with a total small business set-aside. Phase I focuses on delivering a conceptual architecture and a working software prototype, while Phase II, with a ceiling price of 1.5 million dollars, involves full project effort over a 24-month duration. Proposals are evaluated based on technical merit, investigator qualifications, and commercial potential. Applicants must be registered in SAM and the SBA Company Registry. Compliance requirements include CMMC standards for safeguarding controlled unclassified information and strict adherence to organizational conflict of interest disclosures. Proposals must be submitted via the DSIP portal by January 6, 2026.
Defense Threat Reduction Agency

POSTED

2 days ago

DEADLINE

in 2 months
View Details
NAICS: 541714
New
Grant
Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not Allowed)
Solicitation # RFA-AI-28-014
The National Institutes of Health (NIH) issued solicitation RFA-AI-28-014 to establish centers focused on the systems-level understanding of the links between infectious pathogens, inflammatory pathways, and chronic diseases. The program supports two types of centers: Chronic and Infectious Diseases Systems Biology Centers (CIDSB), which examine the bidirectional link between chronic and infectious diseases, and Systems Biology Inflammation Centers (SBI), which focus on the role of inflammation in chronic diseases to identify precision medicine targets. The primary goals are to develop predictive computational models for disease progression, discover novel drug targets and biomarkers, and create harmonized, FAIR-compliant cross-disease datasets. The total program funding is 26 million dollars, with an expected 10 awards and an individual award ceiling of 2.5 million dollars. Applications must be submitted electronically via Grants.gov by February 18, 2027. The proposal structure is multi-component, requiring an overall section, an administrative core, a data and modeling core, and a biospecimen collection and processing core, with additional requirements for research projects and optional cores depending on the center type. Evaluation is based on an overall impact score focusing on significance and the qualifications of the investigators. Awardees must comply with strict cybersecurity incident reporting requirements, notifying the HHS awarding agency within 48 hours of discovery, and must adhere to rigorous biosafety and human subjects protection standards. Applicants must maintain active SAM registration and UEI identifiers to be eligible for funding.
National Institutes Of Health

POSTED

2 days ago

DEADLINE

in 3 months
View Details
NAICS: 541714
New
Grant
In Vivo Efficacy and Toxicology StudiesThis subcontract, titled In Vivo Efficacy and Toxicology Studies, supports the National Institutes of Health and the Department of Health and Human Services by providing preclinical validation of biologic therapies for prime contractors on NIH/NINDS ADRD projects. The scope of work involves executing in vivo efficacy, safety pharmacology, and toxicology studies utilizing translationally appropriate animal models specifically for Alzheimer's and Frontotemporal Dementia. To fulfill the requirements, the contractor must utilize GLP-compliant toxicology lab facilities to ensure regulatory standards are met. The primary deliverables include comprehensive preclinical validation reports and detailed toxicology data packages necessary for Investigational New Drug submission. The project is categorized under NAICS code 541714, with a response deadline set for October 10, 2028.
National Institutes Of Health

POSTED

3 days ago

DEADLINE

in almost 2 years
View Details
NAICS: 541714
New
Grant
Genome Editing Construct and Delivery System OptimizationThis subcontract focuses on the design and optimization of genome editing constructs and biologic delivery systems to support prime contractors on NIH/NINDS genomic therapy projects. The scope of work involves utilizing CRISPR/Cas technology along with viral and non-viral vectors to refine editing constructs and delivery mechanisms. The selected provider will be responsible for assessing critical metrics including bioactivity, target engagement, durability, pharmacokinetics, and bioavailability. The final deliverables for this engagement consist of optimized therapeutic leads accompanied by comprehensive bioactivity and pharmacokinetics data reports.
National Institutes Of Health

POSTED

3 days ago

DEADLINE

in almost 2 years
View Details
NAICS: 541714
New
Grant
NCI Research Specialist (Clinician Scientist)The NCI Research Specialist subcontract involves providing leadership and implementation services for National Cancer Institute funded clinical trials on behalf of prime contractors. The selected clinician scientist will be responsible for writing and revising protocols for national cancer clinical trials, managing trials within a clinical trials office, and recruiting patients. Additionally, the role requires active participation in NCI scientific review, monitoring, and steering committees. Candidates must possess clinician scientist status and demonstrated experience in cancer clinical research. The contract requires a dedicated effort ranging from 2.4 to 4.8 person-months per year. This opportunity is associated with the National Institutes of Health under the Department of Health and Human Services, with a response deadline set for February 20, 2029.
National Institutes Of Health

POSTED

3 days ago

DEADLINE

in over 2 years
View Details
NAICS: 541714
New
Grant
Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
Solicitation # RFA-NS-28-012
The National Institutes of Health, under the Department of Health and Human Services, has issued solicitation RFA-NS-28-012 to support the translation of genome editing and biologic therapies for Alzheimer's Disease-Related Dementias (ADRD). This includes Frontotemporal Dementia, Lewy Body Dementias, Vascular Contributions to Cognitive Impairment and Dementia, and Multiple Etiology Dementias. The program funds the entire translational pipeline, from therapeutic lead optimization and drug product development to IND-enabling studies and early first-in-human clinical evaluations. Key activities include optimizing editing constructs and delivery systems, demonstrating in vivo efficacy, conducting safety pharmacology and toxicology studies, and developing scalable manufacturing processes that align with regulatory expectations. The agency intends to commit 6 million dollars in both fiscal years 2028 and 2029, with an expected three awards and a maximum project period of five years. Individual annual budget caps are set at 1.3 million dollars in direct costs, increasing to 2.5 million dollars for projects involving clinical trials. Awards are governed by the Public Health Service Act and federal regulations 42 CFR Part 52 and 2 CFR Part 200. Evaluation is based on an Overall Impact Score considering significance, innovation, approach, investigator expertise, and environment, with a specific focus on the Target Product Profile and the use of quantitative Go/No-Go milestones. Eligible applicants include small businesses and other for-profit organizations. Requirements for submission include active registration in the System for Award Management, a Unique Entity Identifier, and eRA Commons accounts. Awardees must adhere to strict cybersecurity incident reporting protocols, notifying the agency within 48 hours of discovery, and must register applicable clinical trials with ClinicalTrials.gov. The solicitation features multiple application cycles with deadlines extending through October 10, 2028, and earliest start dates ranging from December 2027 to July 2029.
National Institutes Of Health

POSTED

3 days ago

DEADLINE

in almost 2 years
View Details

More opportunities from National Institutes Of Health → National Institute Of Allergy And Infectious Diseases

Same awarding agency

NAICS: 541714
Grant
Immune Tolerance Network (UM1 Clinical Trial Required)
Solicitation # RFA-AI-28-005
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is seeking applications under solicitation RFA-AI-28-005 to continue the Immune Tolerance Network. The primary goal of this initiative is the development of tolerogenic therapies targeting autoimmune diseases, allergic diseases and asthma, and immune-mediated consequences of transplantation. The network is tasked with the core functions of designing and conducting clinical trials, performing integrated mechanistic studies, and sharing the resulting data. This federal solicitation was posted on October 20, 2026, and requires responses by January 30, 2027. As a UM1 clinical trial requirement, the project emphasizes a collaborative approach to advancing medical treatments for immune-mediated disorders through rigorous clinical research and analysis.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

17 days ago

DEADLINE

in 3 months
View Details
NAICS: 541714
Grant
Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)
Solicitation # RFA-AI-28-012
The National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is soliciting proposals for the Translational Centers Using Microphysiological Systems for Infectious Diseases under solicitation number RFA-AI-28-012. This initiative aims to establish a consortium of centers focused on refining and validating human tissue models to study infectious diseases and test medical interventions. By leveraging New Approach Methodologies, the program seeks to create in vitro systems that capture human variability and patient-specific characteristics, ultimately accelerating the development of safer treatments while reducing costs and the reliance on laboratory animals. The primary objective is to advance these microphysiological systems to a level of regulatory qualification that encourages adoption by product developers and ensures regulatory acceptance. Interested parties must submit their responses by the deadline of January 30, 2027. This federal opportunity specifically focuses on bridging the gap between current research and regulatory use for infectious disease models, though it is noted that clinical trials are not allowed under this specific funding mechanism.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

17 days ago

DEADLINE

in 3 months
View Details
NAICS: 541715
Grant
Centers for AIDS Research (CFAR) and Developmental Centers for AIDS Research (D-CFAR) (P30 Clinical Trial Not Allowed)
Solicitation # PAR-28-090
The National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is soliciting applications for the Centers for AIDS Research and Developmental Centers for AIDS Research programs. This initiative aims to establish administrative and shared research support systems to advance HIV/AIDS research by providing essential infrastructure, expertise, and resources that are typically unavailable through other funding channels. The program specifically prioritizes interdisciplinary collaboration across all research domains related to HIV/AIDS. Identified by solicitation number PAR-28-090, this federal opportunity was posted on October 16, 2026, with a response deadline of May 26, 2029. It is important to note that clinical trials are not allowed under this specific funding mechanism. Interested parties can find further details through the official grants portal.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

21 days ago

DEADLINE

in over 2 years
View Details
NAICS: 541714
Grant
Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)
Solicitation # RFA-AI-28-024
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is seeking proposals under solicitation RFA-AI-28-024 to accelerate the research and preclinical development of next-generation malaria vaccines. This initiative focuses on utilizing structure-based immunogen design, advanced formulations, and combination vaccines to create long-lasting and highly effective protection. The ultimate objective is to enhance public health security in the United States and establish a developmental model that can be applied to other mosquito-borne diseases. This federal solicitation was posted on October 13, 2026, with a response deadline of February 12, 2027. The funding opportunity follows an R61/R33 structure and specifically notes that clinical trials are not allowed. Interested parties can find further details and submission guidelines through the official grants portal.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

24 days ago

DEADLINE

in 3 months
View Details
NAICS: 541715
Grant
Notice of Informational Webinar for RFA-AI-27-018, Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional)
Solicitation # NOT-AI-26-004
The National Institute of Allergy and Infectious Diseases, in collaboration with the Office of AIDS Research and other participating offices, is hosting an informational webinar regarding solicitation RFA-AI-27-018. This initiative focuses on Implementation Science to Advance HIV Prevention, Treatment, and Care under the R61/R33 framework, where clinical trials are optional. The session is designed to allow prospective applicants to learn about key features of the program and engage with Program and Grants Management staff. The webinar is scheduled for October 19, 2026, from 1:30 PM to 3:00 PM EST. While attendance is encouraged to help applicants better understand the requirements, it is not a mandatory prerequisite for submitting an application. Interested parties must register in advance via the provided link, and those requiring reasonable accommodations are asked to submit their requests at least five days before the event.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

30 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional)
Solicitation # RFA-AI-27-018
The National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is seeking proposals for the Implementation Science to Advance HIV Prevention, Treatment, and Care initiative. This solicitation, identified as RFA-AI-27-018, focuses on supporting implementation research designed to enhance the uptake, sustainment, scale, and spread of evidence-based interventions within U.S. communities heavily impacted by HIV. The agency is prioritizing large-scale projects with significant potential for public health impact, specifically encouraging the submission of multi-site, single-site, or comparative studies. This funding opportunity is structured as an R61/R33 clinical trial optional award. Interested parties must submit their responses by the deadline of June 21, 2029. The primary goal of the selected projects will be to bridge the gap between evidence-based prevention and treatment strategies and their practical application in real-world community settings to improve overall health outcomes.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

about 1 month ago

DEADLINE

in over 2 years
View Details
NAICS: 541714
Grant
Centers for Structural Biology of HIV and Other Infectious Diseases (U54 Clinical Trial Not Allowed)
Solicitation # RFA-AI-28-031
The National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is seeking applications for the Centers for Structural Biology of HIV and Other Infectious Diseases under solicitation RFA-AI-28-031. This funding opportunity aims to establish multidisciplinary consortia comprising structural biologists, microbiologists, and other experts dedicated to solving complex biological structures to advance the prevention, treatment, and cure of HIV and various other infectious diseases. Selected centers are expected to foster new collaborations, manage shared resources, and provide essential services to the broader research community while training future scientists in the field. The response deadline for this solicitation is May 29, 2027, and clinical trials are not allowed under this specific grant.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

about 1 month ago

DEADLINE

in 7 months
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS